AIM ImmunoTech CEO and President Thomas K. Equels bought 11,000 shares at $0.21 each, lifting his reported holding to 102,822 shares. The purchase equals about 10.7% of his resulting position, giving investors a precise measure of the transaction relative to his reported stake.

Key Highlights

  • Thomas K. Equels’ AIM ImmunoTech purchase was executed at $0.21 per share.
  • His reported ownership after the transaction stood at 102,822 shares.
  • The purchase represented about 10.7% of his resulting AIM ImmunoTech holding.

AIM ImmunoTech Inc. (AMEX: AIM) is a Pharmaceuticals: Major company. CEO and President Thomas K. Equels purchased 11,000 shares in the Business at $0.21 per share on September 16, 2026. The transaction leaves Equels with 102,822 shares.

Equels Adds 11,000 AIM ImmunoTech Shares

Equels bought the shares at the stated price of $0.21 each. AIM ImmunoTech’s reported ownership figure for Equels after the purchase is 102,822 shares. The transaction accounts for about 10.7% of his resulting shares holding.